These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 7533459)

  • 21. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome.
    Zietman AL; Coen JJ; Dallow KC; Shipley WU
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):287-92. PubMed ID: 7751173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
    Zagars GK; Kavadi VS; Pollack A; von Eschenbach AC; Sands ME
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):21-32. PubMed ID: 7536722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.
    Fowler JE; Pandey P; Braswell NT; Seaver L
    Surgery; 1994 Aug; 116(2):302-5; discussion 305-6. PubMed ID: 7519363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
    Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
    J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
    Pollack A; Zagars GK; Kopplin S
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):13-20. PubMed ID: 7536720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy.
    Bales GT; Williams MJ; Sinner M; Thisted RA; Chodak GW
    Urology; 1995 Nov; 46(5):676-80. PubMed ID: 7495120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
    Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen.
    Swanson GP; Du F; Michalek JE; Hermans M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):62-8. PubMed ID: 20646861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors affecting progression and survival in metastatic prostate cancer.
    Nayyar R; Sharma N; Gupta NP
    Urol Int; 2010; 84(2):159-63. PubMed ID: 20215819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone?
    Lee WR; Hanlon AL; Hanks GE
    Radiology; 1996 Feb; 198(2):439-42. PubMed ID: 8596846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate.
    Roach M; Meehan S; Kroll S; Weil M; Ryu J; Small EJ; Margolis LW; Presti J; Carroll PC; Phillips TL
    J Urol; 1996 Nov; 156(5):1719-23. PubMed ID: 8863578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment prostate-specific antigen values in patients with prostate cancer: 1989 patterns of care study process survey.
    Teshima T; Hanlon AM; Hanks GE
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):809-14. PubMed ID: 7591887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review.
    Fiveash JB; Hanks G; Roach M; Wang S; Vigneault E; McLaughlin PW; Sandler HM
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):335-42. PubMed ID: 10802357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
    Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
    J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
    Kavadi VS; Zagars GK; Pollack A
    Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
    Lee WR; Hanlon AL; Hanks GE
    J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate.
    McLean M; Panzarella T; Warde PR; Gospodarowicz M; Duncan W; Catton C; Bissett R
    Clin Oncol (R Coll Radiol); 1997; 9(4):226-33. PubMed ID: 9315396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
    Aref I; Eapen L; Agboola O; Cross P
    Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
    Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
    J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.